On September 9, 2025, Vistagen Therapeutics reported that CFO Cynthia L. Anderson will resign effective October 15, 2025, and will assist in the transition. The company also held its annual meeting where directors were elected and executive compensation was approved, with votes reflecting significant stockholder support.